W

hat does the rest of 2018 have in store for biotech?

On Tuesday, we hosted a conference call with STAT Plus subscribers to briefly recap the year so far and chew over some of the major biotech events we’re looking out for in the coming months. That means discussing Celgene’s upcoming cancer data, Sarepta Therapeutics’ future in gene therapy, the gene-editing prospects for Sangamo Therapeutics, and the risks surrounding Esperion Therapeutics’ cholesterol drug. We also touched on Amarin, Global Blood Therapeutics, and the existential crisis facing large-cap biotech companies.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy